Advertisement

Drugs

, Volume 21, Issue 2, pp 81–89 | Cite as

α-Methyl-p-Tyrosine: A Review of its Pharmacology and Clinical Use

  • R. N. Brogden
  • R. C. Heel
  • T. M. Speight
  • G. S. Avery
Evaluations on New Drugs

Summary

Synopsis

α-Methyl-p-tyrosine1,2 is an orally active inhibitor of catecholamine synthesis which inhibits the hydroxylation of tyrosine to dopa. At dosages of 600 to 3500mg daily it is effective in controlling the hypertensive episodes and symptoms of catecholamine excess in phaeochromocytoma during preparation for surgery. Limited published experience suggests that it is effective in controlling hypertension and symptoms in malignant phaeochromocytoma, but further long term experience is needed. Concomitant administration of phenoxybenzamine and propranolol may be desirable in some patients and treatment with phentolamine is usually necessary to control hypertension during manipulation of the tumour.

Pharmacology

α-Methyl-p-tyrosine is an inhibitor of catecholamine synthesis peripherally as well as centrally and achieves this by inhibiting the hydroxylation of tyrosine to form dopa. The inhibition of catecholamine synthesis is evidenced by the dose-related reduction of urinary catecholamines and their metabolites when the drug is given at daily dosages of up to 1500mg. There is a further reduction at higher dosages but the magnitude of the decrease is proportionally less as dosage increases.

α-Methyl-p-tyrosine usually decreases blood pressure in patients with phaeochromocytoma but does not consistently decrease blood pressure in patients with essential hypertension. As α-methyl-p-tyrosine treatment may interfere with standard methods of estimation of urinary catecholamines it is advisable to determine total catecholamines as well as hydroxymethoxymandelic acid3 and methylated catecholamines.

Pharmacokinetics

Oral α-methyl-p-tyrosine is well absorbed and absorption appears constant in each individual over a wide dosage range. The drug is largely excreted via the kidneys, but extrarenal elimination has not been studied. The drug is metabolised to only a limited extent.

Therapeutic Studies

Case reports on the clinical use of α-methyl-p-tyrosine in phaeochromocytoma indicate that the drug controls hypertension and symptoms of catecholamine excess in most patients during preparation for surgical removal of the tumour. In some cases the addition of α-methyl-p-tyrosine to phenoxybenzamine plus propranolol has resulted in adequate control of symptoms previously unresponsive to the adrenergic blocking regimen. The opportunity to study the relative merit of using α-methyl-p-tyrosine alone or combined with adrenergic blocking drugs has seldom arisen, but in a patient with bilateral phaeochromocytoma, the use of α-methyl-p-tyrosine plus adrenergic blocking drugs resulted in a smoother pre- and postoperative course than α-methyl-p-tyrosine alone.

Long term administration of α-methyl-p-tyrosine in malignant phaeochromocytoma is limited, but the data available suggest that the drug can adequately control symptoms for periods of many months. The question as to whether or not tolerance occasionally develops to the therapeutic effects of the drug in phaeochromocytoma has not been fully clarified.

Keywords

Catecholamine Propranolol Phaeochromocytoma Phenoxybenzamine Urinary Catecholamine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Amery, A.; Moerman, E.J.; Bossaert, H. and de Schaepdryver, A.F.: α-Methyl-p-tyrosine in malignant pheochromocytoma. Pharmacologia Clinica 1: 174–176 (1969).CrossRefGoogle Scholar
  2. Bagnall, W.E.; Salway, J.G. and Jackson, E.W.: Phaeochromocytoma with myocarditis managed with α-methyl-p-tyrosine. Postgraduate Medical Journal 52: 653–656 (1976).CrossRefGoogle Scholar
  3. Bergman, S.M.; Sears, H.F.; Javadpour, N. and Keiser, H.R.: Postoperative management of patients with pheochromocytoma. Journal of Urology 120: 109–112 (1978).PubMedGoogle Scholar
  4. Brodie, H.K.H.; Murphy, D.L.; Goodwin, F.K. and Bunney, W.E. Jr.: Catecholamines and mania: the effect of alphamethyl-para-tyrosine on manic behaviour ana catecholamine metabolism. Clinical Pharmacology and Therapeutics 12 (part 1): 218–224 (1971).PubMedGoogle Scholar
  5. Bunney, W.E. jr; Brodie, H.K.H.; Murphy, D.L. and Goodwin, F.K.: Studies of alpha-methyl-para-tyrosine, L-dopa, and L-tryptophan in depression and mania. American Journal of Psychiatry 127: 872–881 (1971).PubMedGoogle Scholar
  6. Carlsson, A.; Roos, B.-E.; Walinder, J. and Skott, A.: Further studies on the mechanism of antipsychotic action: potentiation by α-methyltyrosine of thioridazine effects in chronic schizophrenics. Journal of Neural Transmission 34: 125–132 (1973).PubMedCrossRefGoogle Scholar
  7. Charalampous, K.D. and Brown, S.: A clinical trial of α-methyl-para-tyrosine in mentally ill patients. Psychopharmacologia (Berlin) 11: 422–429 (1967).CrossRefGoogle Scholar
  8. DeQuattro, V. and Sjoerdsma, A.: Catecholamine turnover in nor-motensive and hypertensive man: effects of antiadrenergic drugs. Journal of Clinical Investigation 47: 2359–2373 (1968).PubMedCrossRefGoogle Scholar
  9. Engelman, K. and Sjoerdsma, A.: Inhibition of catecholamine biosynthesis in man. Circulation Research 18(Suppl.I) l: 104–109 (1966).Google Scholar
  10. Engelman, K.; Jéquier, E.; Udenfriend, S. and Sjoerdsma, A.: Metabolism of α-methyltyrosine in man: relationship to its potency as an inhibitor of catecholamine biosynthesis. Journal of Clinical Investigation 47: 568–576 (1968a).PubMedCrossRefGoogle Scholar
  11. Engelman, K.; Horwitz, D.; Jéquier, E. and Sjoerdsma, A.: Biochemical and pharmacologic effects of α-methyltyrosine in man. Journal of Clinical Investigation 47: 577–594 (1968b).PubMedCrossRefGoogle Scholar
  12. Havers, L. and Bayer, J.M.: Drug inhibition of catecholamine synthesis in pheochromocytoma. Anaesthesiology Wiederbeleb. 56: 110–115 (1972).Google Scholar
  13. Hengstmann, J.H.; Gugler, R. and Dengler, H.J.: Malignant phaeochromocytoma. Effect of oral α-methyl-p-tyrosine upon catecholamine metabolism. Klinische Wochenschrift 57: 351–355 (1979).PubMedCrossRefGoogle Scholar
  14. Jones, N.F.; Walker, G.; Ruthven, C.R.J. and Sandler, M.: α-Methyl-p-tyrosine in the management of phaeochromocytoma. Lancet 2: 1105–1110 (1968).PubMedCrossRefGoogle Scholar
  15. McCarthy, E.F.; Bonfiglio, M. and Lawton, W.: A solitary functioning osseous metastasis from a malignant pheochromocytoma of the organ of Zuckerkandl. Cancer Philadelphic 40: 3092–3096 (1977).CrossRefGoogle Scholar
  16. Magelund, G.; Gerlach, J. and Casey, D.E.: Neuroleptic-potentiating effect of α-methyl-p-tyrosine compared with haloperidol and placebo in a double-blind cross-over trial. Acta Psychiatrica Scandinavica 60: 185–189 (1979).PubMedCrossRefGoogle Scholar
  17. Parra, A.; Porcayo, F. and Santos, D.: Phaeochromocytoma: urinary catecholamine excretion and insulin secretion after α-methyl-p-tyrosine treatment. Helvetica Paediatrica Acta 27: 309–314 (1972).PubMedGoogle Scholar
  18. Porter, C.C.; Totaro, J.A.; Burcin, A. and Wynosky, E.R.: The effect of the optical isomers of α-methyl-p-tyrosine upon brain and heart catecholamines in the mouse. Biochemical Pharmacology 15: 583–390 (1965).CrossRefGoogle Scholar
  19. Pyörälä, K.; Pitkänen, E. and Toivonen, S.: α-Methyl-p-tyrosine in the symptomatic treatment of patients with malignant phaeochromocytoma. Annales Medicinae Interne Fenniae 57: 65–73 (1968).Google Scholar
  20. Robinson, R.G.; DeQuattro, V.; Grushkin, C.M. and Lieberman, E.: Childhood pheochromocytoma. Treatment with alpha methyl tyrosine for resistant hypertension. Journal of Pediatrics 91: 143–147 (1977).PubMedCrossRefGoogle Scholar
  21. Serrano, P.A.; Zajarias, S.; Torres, Z.M. and Chaves Lara, B.: The excretion of adrenaline, noradrenaline and dopamine in cases of pheochromocytoma treated with alpha-methyl-tyrosine. Acta Endocrinologica. Panamerica 2: 159–170 (1971).Google Scholar
  22. Sjoerdsma, A.: E. Catecholamine-drug interactions in man. Pharmacological Reviews 18: 673–683 (1966).PubMedGoogle Scholar
  23. Sjoerdsma, A.: Catecholamines and the drug therapy of hypertension. Circulation Research (Suppl III) 21: 119–125 (1967).Google Scholar
  24. Sjoerdsma, A.; Engelamn, K.; Spector, S. and Udenfriend, S.: Inhibition of catecholamine synthesis in man with alpha-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. Lancet 2: 1092–1094 (1965).PubMedCrossRefGoogle Scholar
  25. Sweet, R.D.; Bruun, R.; Shapiro, E. and Shapiro, A.K.: Presynaptic catecholamine antagonists as treatment for Tourette syndrome. Effects of alpha methyl para tyrosine and tetrabenazine. Archives of General Psychiatry 31: 857–861 (1974).PubMedCrossRefGoogle Scholar
  26. Tcherdakoff, Ph.; Menard, J.; Bedrossian, J.; Vaysse, J.; Alexandre, J.M. and Milliez, P.: Malignant phaeochromocytoma with metastasis: treatment with alpha-methyl-para-tyrosine. Semaine des Hôpitaux 48: 1779–1787 (1972a).PubMedGoogle Scholar
  27. Tcherdakoff, P.; Menard, J.; Bedrossian, J.; Vaysse, J.; Alexandre, J.M.; Desmonts, J.M. and Milliez, P.: Alpha-methyl-para-tyrosine in the prolonged therapy of malignant phaeochromocytoma and preoperative treatment for benign pheochromocytoma: preliminary study. Journal d’Urologie et de Nephrologie 78: 744–747 (1972b).PubMedGoogle Scholar

Copyright information

© ADIS Press Australasia Pty Ltd 1981

Authors and Affiliations

  • R. N. Brogden
    • 1
  • R. C. Heel
    • 1
  • T. M. Speight
    • 1
  • G. S. Avery
    • 1
  1. 1.Australasian Drug Information ServicesBirkenhead, Auckland 10New Zealand

Personalised recommendations